These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23256630)

  • 1. [Oxidative stress after anthracycline therapy in patients with solid tumors].
    Kocik M; Zimovjanova M; Petruzelka L; Kodydkova J; Vavrova L; Zak A
    Cas Lek Cesk; 2012; 151(10):463-7. PubMed ID: 23256630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of anthracyclines in the era of targeted therapy.
    Cortés-Funes H; Coronado C
    Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.
    Pinarli FG; Oğuz A; Tunaoğlu FS; Karadeniz C; Gökçora N; Elbeg S
    Pediatr Blood Cancer; 2005 Apr; 44(4):370-7. PubMed ID: 15602715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic stress echocardiography in asymptomatic patients who received chemotherapy in childhood because of a malignant disease.
    Elbl L; Hrstkova H; Chaloupka V; Michalek J
    Kardiol Pol; 2003 Mar; 58(3):190-6. PubMed ID: 14513093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor and non-tumor tissues differential oxidative stress response to supplemental DHA and chemotherapy in rats.
    Hajjaji N; Besson P; Bougnoux P
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):17-23. PubMed ID: 22610354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Value of cardiac troponin I measurement in prediction of anthracycline-induced cardiotoxicity in breast cancer patients].
    Huang WB; Yao GY; Liu MF; Chen RT; Chen LJ; Dong JY; Gu F; Guo ZZ; Ye CS
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1047-50. PubMed ID: 21690066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children.
    Aggarwal S; Pettersen MD; Bhambhani K; Gurczynski J; Thomas R; L'Ecuyer T
    Pediatr Blood Cancer; 2007 Nov; 49(6):812-6. PubMed ID: 17171687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.
    Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M
    J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
    Conklin KA
    Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.
    Silber JH; Cnaan A; Clark BJ; Paridon SM; Chin AJ; Rychik J; Hogarty AN; Cohen MI; Barber G; Rutkowsky M; Kimball TR; Delaat C; Steinherz LJ; Zhao H; Tartaglione MR
    Am Heart J; 2001 Oct; 142(4):577-85. PubMed ID: 11579345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
    van Dalen EC; van der Pal HJ; Kok WE; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3191-8. PubMed ID: 16987655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
    Menna P; Recalcati S; Cairo G; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of multiple antioxidants Chinese herbal medicine on the oxidative stress induced by adriamycin chemotherapy.
    Qin XJ; He W; Hai CX; Liang X; Liu R
    J Appl Toxicol; 2008 Apr; 28(3):271-82. PubMed ID: 17582587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of anthracycline-induced cardiotoxicity with electrocardiography.
    Horacek JM; Jakl M; Horackova J; Pudil R; Jebavy L; Maly J
    Exp Oncol; 2009 Jun; 31(2):115-7. PubMed ID: 19550402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
    van Dalen EC; van den Brug M; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid peroxidation and antioxidant enzyme activities in erythrocytes of type 2 diabetic patients.
    Likidlilid A; Patchanans N; Peerapatdit T; Sriratanasathavorn C
    J Med Assoc Thai; 2010 Jun; 93(6):682-93. PubMed ID: 20572373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ongoing phase I and II studies of novel anthracyclines.
    Sessa C; Valota O; Geroni C
    Cardiovasc Toxicol; 2007; 7(2):75-9. PubMed ID: 17652808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.